# EDGAR Filing Document

**Accession Number:** 0001351172
**File Stem:** 0001279569-23-000177
**Filing Date:** 2023-2
**Character Count:** 7452
**Document Hash:** da8c0717cec9181f5e30198314925176
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001279569-23-000177.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001279569-23-000177

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230215

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Liminal BioSciences Inc.
- **CENTRAL INDEX KEY:** 0001351172
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39131
- **FILM NUMBER:** 23636152

**BUSINESS ADDRESS:**
- **STREET 1:** 231 DUNDAS STREET EAST
- **CITY:** BELLEVILLE
- **STATE:** A6
- **ZIP:** K8N 1E2
- **BUSINESS PHONE:** 450-781-0115

**MAIL ADDRESS:**
- **STREET 1:** 440 ARMAND-FRAPPIER BLVD.
- **STREET 2:** SUITE 300
- **CITY:** LAVAL
- **STATE:** A8
- **ZIP:** H7V 4B4

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ProMetic Life Sciences Inc
- **DATE OF NAME CHANGE:** 20060126

**UNITED STATES SECURITIES**

**AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the Month of February 2023**

**Commission File Number: 001-39131**

**LIMINAL BIOSCIENCES INC.**

**(Translation of registrant's name into English)**

**440 Armand-Frappier Boulevard, Suite 300**

**Laval, Québec**

**H7V 4B4**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: ☒ Form 20-F ☐ Form 40-F

**<u>INCORPORATION BY REFERENCE</u>**

This Report on Form 6-K (the "Report") and Exhibit 99.1 to this Report are hereby expressly incorporated by reference into the registrant's registration statements on Form F-3 (File nos. 333-251055, 333-245703 and 333-251065) filed with the Securities and Exchange Commission on December 1, 2020, December 2, 2020 and December 2, 2020, respectively, and the registration statement on Form S-8 (File no. 333-235692) filed with the Securities and Exchange Commission on December 23, 2019.

**<u>EXHIBIT LIST</u>**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [99.1](ex991.htm) | [Press Release dated February 15, 2023](ex991.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** | **Liminal BioSciences Inc.** |
| Date: February 15, 2023 | By: | /s/ Bruce Pritchard | /s/ Bruce Pritchard |
|  |  | Name | Bruce Pritchard |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

![](logo.jpg)

**Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement**

LAVAL, QC, Feb. 15, 2023 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced that it has received written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Capital Market. The notice indicated that, as a result of the closing bid price of the Company's common stock having been $1.00 per share or greater for at least ten consecutive business days, from February 1, 2023 through February 14, 2023, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1).

**About Liminal BioSciences Inc.**

Liminal BioSciences is a development-stage biopharmaceutical company focused on discovering and developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using our drug discovery platform with a data-driven approach. The Company's lead program is LMNL6511, a selective antagonist for the GPR84 receptor, and the Company is also developing potential OXER1 antagonists. In addition to these programs, the Company continues to explore other development opportunities to add to its pipeline.

Liminal BioSciences has active business operations in Canada and the United Kingdom.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words "anticipate," "expect," "suggest," "plan," "believe," "intend," "estimate," "target," "project," "should," "could," "would," "may," "will," "forecast" and other similar expressions are intended to identify forward-looking statements. Forward–looking statements include, among other things, the potential development of Liminal Biosciences' R&D programs and the Company's ability to meet Nasdaq continued listing requirements. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Among the factors that could cause actual results to differ materially from those described or projected herein include, but are not limited to, risks associated with general changes in economic conditions. You will find a more detailed assessment of these risks, uncertainties and other risks that could cause actual events or results to materially differ from our current expectations in the filings and reports the Company makes with the U.S. Securities and Exchange Commission and Canadian Securities Administrators, including in the Annual Report on Form 20-F for the year ended December 31, 2021, as well as other filings and reports Liminal Biosciences' may make from time to time. As a result of such risks, we cannot guarantee that any given forward-looking statement will materialize. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. We assume no obligation to update any forward-looking statement contained in this press release even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

View original content to download multimedia:https://www.prnewswire.com/news-releases/liminal-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement-301748062.html

SOURCE Liminal BioSciences Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February 2023/15/c0511.html

%CIK: 0001351172

**For further information:** Corporate Contact, Shrinal Inamdar, Associate Director, Investor Relations and Communications, s.inamdar@liminalbiosciences.com, +1 450.781.0115; Media Contact: Kaitlin Gallagher, kgallagher@berrypr.com, +1 212.253.8881

CO: Liminal BioSciences Inc.

CNW 16:05e 15-FEB-23